Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 16/20 | 0.38 |
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.38 |
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.38 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.37 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.37 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.37 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.37 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.33 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.33 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250057 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL4938994 | 0.88 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL3774679 | 0.86 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL1746181 | 0.84 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL9583153 | 0.83 | — | — | |
| SCHEMBL25111996 | 0.80 | — | — | |
| SCHEMBL907341 | 0.80 | — | — | |
| SCHEMBL11652607 | 0.80 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL8005749 | 0.79 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL9696636 | 0.79 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752257-A | Hypervalent iodine reagent mediation prepares the application of indole derivatives | 南开大学 | 2018-11-06 | — | — | CN | claimed |
| CN-101870683-B | Method for preparing pinaverium bromide and intermediate compound of pinaverium bromide | SHANGHAI SINCH PHARMACEUTICALS TECH CO LTD | 2012-09-26 | — | — | CN | claimed |
| CN-101870683-A | Method for preparing pinaverium bromide and intermediate compound of pinaverium bromide | SHANGHAI SINCH PHARMACEUTICALS TECH CO LTD | 2010-10-27 | — | — | CN | claimed |
| EP-3837241-B1 | FLUORO SS-CARBOLINE COMPOUNDS FOR THE TREATMENT OF BONE HOMEOSTASIS | OSSIFI THERAPEUTICS LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097041-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | OSSIFI THERAPEUTICS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| CN-120647576-A | Preparation method of morpholinyl fluoride | 陕西宝新药业有限公司 | 2025-09-16 | — | — | CN | disclosed |
| US-12324809-B2 | Fluoro beta-carboline compounds | OSSIFI THERAPEUTICS LLC (US) | 2025-06-10 | — | — | US | disclosed |
| WO-2025024159-A1 | FABRIC SOFTENING FORMULATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20250025472-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | OSSIFI THERAPEUTICS LLC | 2025-01-23 | — | — | US | disclosed |
| CN-118742288-A | Hair conditioner formulations based on modified dextran polymers | 罗门哈斯公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| CN-86104668-A | Soft soldering flux and prescription thereof | — | 1987-09-02 | — | — | CN | disclosed |
| EP-0169581-A2 | Antitussive and mucus regulating 2-substituted thiazolidines | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1986-01-29 | — | — | EP | disclosed |
| US-4443603-A | PROTEOLYTIC ENZYME INHIBITORS | KOWA COMPANY LIMITED (JP) | 1984-04-17 | — | — | US | disclosed |
| US-4380518-A | Method of producing solder spheres | WESTERN ELECTRIC COMPANY, INC. (US) | 1983-04-19 | — | — | US | disclosed |
| EP-0071433-A1 | Medicine for the treatment of diabetes | KOWA COMPANY, LTD. (JP) | 1983-02-09 | — | — | EP | disclosed |
| EP-0067561-A2 | Piperazine derivatives and processes for producing them | KOWA COMPANY, LTD. (JP) | 1982-12-22 | — | — | EP | disclosed |
| US-RE30696-E | COMPRISING AN ESTER OF A POLYHYDRIC ALCOHOL, AN ACID, AN ACTIVATOR, AND A HARDENER; PRINTED CIRCUITS | MULTICORE SOLDERS LIMITED (GB) | 1981-08-04 | — | — | US | disclosed |
| US-4139620-A | HYPOTENSIVE AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4096331-A | HYPOTENSIVE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025472-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | GLS, AFF1, SLC5A1 | SLC6A2 3066/4885SLC6A4 3009/4885SLC6A3 2054/4885 |
| US-20260097041-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | CTNNB1, SLC5A1, SLC5A2 | SLC6A2 101/4885SLC6A4 169/4885SLC6A3 122/4885 |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | SLC6A2 4860/4885SLC6A4 4822/4885SLC6A3 4671/4885 |
| US-12324809-B2 | Fluoro beta-carboline compounds | GLS, AFF1, SLC5A1 | SLC6A2 3066/4885SLC6A4 3009/4885SLC6A3 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.